"目录号: HY-14262
GPCR/G ProteinNeuronal Signaling-
Vilazodone(EMD 68843; SB 659746A)是五羟色胺重吸收抑制剂（SSRI）和5-HT1A受体部分激动剂。
5-HT ReceptorSerotonin Transporter
相关产品
Clozapine N-oxide-Chlorpromazine hydrochloride-Pimavanserin-Fluoxetine hydrochloride-Brexpiprazole-Lorcaserin Hydrochloride-Scopolamine hydrobromide-Paroxetine hydrochloride-Cariprazine hydrochloride-Harmine-Lu AE58054 Hydrochloride-TG6-10-1-Duloxetine hydrochloride-Perphenazine-Sertraline hydrochloride-
生物活性
Description
Vilazodone (EMD 68843; SB 659746A) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation for the treatment of major depression.IC50 value:Target: SSRI; 5-HT1AVilazodone represents another option for the treatment of MDD. Vilazodone appears to have a favourable weight-gain profile based on short-term studies. Sexual side-effects were not consistently demonstrated when assessed using clinical rating scales but spontaneously reported AEs related to sexual functioning were observed. Additional controlled data regarding long-term efficacy and effectiveness will help characterise this new agent when used in maintenance treatment.
Clinical Trial
NCT02015546
Duke University
Major Depressive Disorder (MDD)
December 2012
Phase 3
NCT01828515
University of Texas Southwestern Medical Center-Forest Laboratories
Memory Impairment
December 2012
Phase 2
NCT02436239
Forest Laboratories
Major Depressive Disorder
May 2015
Phase 3
NCT01712321
The Medical Research Network-Forest Laboratories
Social Anxiety Disorder
October 2012
NCT00644358
Forest Laboratories
Major Depressive Disorder
December 2007
Phase 3
NCT01473394
Forest Laboratories
Major Depressive Disorder
December 2011
Phase 4
NCT01844115
Forest Laboratories
Generalized Anxiety Disorder
April 2013
Phase 3
NCT01856127
Thomas Jefferson University-Forest Laboratories
Sexual Dysfunction-Major Depressive Disorder
January 2013
Phase 4
NCT01574183
Medical University of South Carolina-National Institute on Drug Abuse (NIDA)
Marijuana Dependence
August 2012
Phase 2
NCT01573598
Forest Laboratories
Major Depressive Disorder
April 2012
Phase 4
NCT01878292
Forest Laboratories
Major Depressive Disorder
July 2013
Phase 3
NCT01999920
New York State Psychiatric Institute-Forest Laboratories
Separation Anxiety Disorder
December 2013
Phase 4
NCT01680900
University of Pennsylvania-Forest Laboratories
Hot Flushes
November 2012
NCT01608295
University of California, Los Angeles-Forest Laboratories
Major Depressive Disorder
July 2012
Phase 4
NCT00285376
Genaissance Pharmaceuticals
Depressive Disorder, Major
February 2006
Phase 3
NCT01742832
University of Chicago
Major Depressive Disorder
May 2013
Phase 2
NCT00683592
Forest Laboratories
Major Depressive Disorder
March 2008
Phase 3
NCT02028026
Massachusetts General Hospital
Major Depressive Disorder-Anxiety-Comorbidity
April 2013
Phase 4
NCT02097147
Forest Laboratories
Healthy
March 2014
Phase 1
NCT01629966
Forest Laboratories
Generalized Anxiety Disorder
June 2012
Phase 3
NCT02372799
Forest Laboratories
Major Depressive Disorder
February 2015
Phase 3
NCT01473381
Forest Laboratories
Major Depressive Disorder
December 2011
Phase 4
NCT00290914
Pharmacology Research Institute
Major Depressive Disorder
Phase 2
View MoreCollapse
References
[1].Cruz MP. Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
[2].Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J C
[3].Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr Med Res Opin. 2012 Jan;28(1):27-39.
[4].Lee A. Dawson et al. Vilazodone: A 5-HT1A Receptor Agonist/Serotonin Transporter Inhibitor for the Treatment of Affective Disorders CNS Neuroscience & Therapeutics Volume 15, Issue 2, pages 107-117, June 2009
[5].Thomas L. Schwartz Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor Therapeutic Advances in Psychopharmacology June 2011 vol. 1 no. 3 81-87